AIM: To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions. METHODS: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria. RESULTS: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion. CONCLUSION: The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution / F. Pessina, P. Navarria, L. Cozzi, S. Tomatis, E. Clerici, A.M. Ascolese, M. Simonelli, M. Perrino, M. Riva, M. Rossi, R. Rudà, A. Santoro, L. Bello, M. Scorsetti. - In: CNS ONCOLOGY. - ISSN 2045-0907. - 6:3(2017), pp. 211-219. [10.2217/cns-2016-0043]
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution
M. Riva;M. Rossi;L. Bello;
2017
Abstract
AIM: To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions. METHODS: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria. RESULTS: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion. CONCLUSION: The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.File | Dimensione | Formato | |
---|---|---|---|
pessina2017.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.61 MB
Formato
Adobe PDF
|
1.61 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.